[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR2288527A2 - Oil-free adjuvant compsns causing no hypersensitisation - contg N-acetyl-muramyl-L-alanyl-D-isoglutamine pref in aq soln - Google Patents

Oil-free adjuvant compsns causing no hypersensitisation - contg N-acetyl-muramyl-L-alanyl-D-isoglutamine pref in aq soln

Info

Publication number
FR2288527A2
FR2288527A2 FR7529624A FR7529624A FR2288527A2 FR 2288527 A2 FR2288527 A2 FR 2288527A2 FR 7529624 A FR7529624 A FR 7529624A FR 7529624 A FR7529624 A FR 7529624A FR 2288527 A2 FR2288527 A2 FR 2288527A2
Authority
FR
France
Prior art keywords
oil
compsns
isoglutamine
alanyl
contg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7529624A
Other languages
French (fr)
Other versions
FR2288527B2 (en
Inventor
Francoise Audibert
Louis Chedid
Pierre Lefrancier
Jean Choay
Edgar Lederer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bpifrance Financement SA
Original Assignee
Agence National de Valorisation de la Recherche ANVAR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/516,991 external-priority patent/US4186194A/en
Application filed by Agence National de Valorisation de la Recherche ANVAR filed Critical Agence National de Valorisation de la Recherche ANVAR
Priority to IL48325A priority Critical patent/IL48325A/en
Priority to NL7512326A priority patent/NL7512326A/en
Priority to DE19752547104 priority patent/DE2547104A1/en
Priority to NL7512325A priority patent/NL7512325A/en
Priority to GB43079/75A priority patent/GB1531244A/en
Priority to GB43080/75A priority patent/GB1531014A/en
Priority to DE19752547105 priority patent/DE2547105A1/en
Priority to AU85917/75A priority patent/AU503714B2/en
Priority to US05/624,994 priority patent/US4158052A/en
Priority to US05/625,195 priority patent/US4172125A/en
Priority to CA240,142A priority patent/CA1060796A/en
Priority to CA240,116A priority patent/CA1060795A/en
Publication of FR2288527A2 publication Critical patent/FR2288527A2/en
Priority to JP51113813A priority patent/JPS5244223A/en
Priority to JP51113812A priority patent/JPS5241211A/en
Publication of FR2288527B2 publication Critical patent/FR2288527B2/fr
Application granted granted Critical
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/5555Muramyl dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Novel oil-free adjuvant compsns. contain N-acetylmuramyl-L-alanyl-D-isoglutamine (I) as active principle together with a pharmaceutically acceptable vehicle, prefd. being sterile injectable aaq. solns. of (I). Also claimed are lyophilised (I) prepns. suitable for preparing such solns. (I) has high non-specific adjuvant activity in aq. soln. and in physiological lquids (unlike prior art non-specific adjuants), and also does not induce host sensitisation to (I) or other adjuvants prefd. from mycobacteria. Compared with the use of (I) in water-oil emulsions as in the parent patent, difficulties due to the non-metabolisable nature of the oil and harmfulness of emulsion stabilisers are avoided. The compsns. increase the effectiveness of bacterial or viral vaccines, and are esp. for increasing the immunity of human or animal hosts to bacterial or viral infections, tumour antigens, protozoal antigens etc. They are also useful for making sera contg. antibodies active towards these antigents.
FR7529624A 1974-10-22 1975-09-26 Oil-free adjuvant compsns causing no hypersensitisation - contg N-acetyl-muramyl-L-alanyl-D-isoglutamine pref in aq soln Granted FR2288527A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IL48325A IL48325A (en) 1974-10-22 1975-10-20 Immunological-free adjuvant compositions containing n-acetyl muramyl-alanyl-d-isoglutamine or n-acetyl-muramyl-l-alanyl-d-glutamicn acid
NL7512326A NL7512326A (en) 1974-10-22 1975-10-21 METHOD OF PREPARING A MEDICINAL PRODUCT.
DE19752547104 DE2547104A1 (en) 1974-10-22 1975-10-21 OIL-FREE ADJUVANCES CONTAINING N-ACETYL-MURAMYL-L-ALANYL-D-GLUTAMIC ACID
NL7512325A NL7512325A (en) 1974-10-22 1975-10-21 METHOD OF PREPARING A MEDICINAL PRODUCT.
GB43079/75A GB1531244A (en) 1974-10-22 1975-10-21 Oil-free adjuvant composition
GB43080/75A GB1531014A (en) 1974-10-22 1975-10-21 Oil-free adjuvant composition
DE19752547105 DE2547105A1 (en) 1974-10-22 1975-10-21 N-ACETYL-MURAMYL-L-ALANYL-D-ISOGLUTAMINE CONTAINING OIL-FREE ADJUVANCES
US05/624,994 US4158052A (en) 1974-10-22 1975-10-22 Oil-free adjuvant compositions containing N-acetyl-muramyl-L-alanyl-D-isoglutamine
AU85917/75A AU503714B2 (en) 1974-10-22 1975-10-22 Oil-free adjuvant composition
US05/625,195 US4172125A (en) 1974-10-22 1975-10-23 Oil-free adjuvant compositions containing N-acetyl-muramyl-L-alanyl-D-glutamic acid and method of use
CA240,142A CA1060796A (en) 1975-09-26 1975-11-20 Oil-free adjuvant composition containing muramyl dipeptide
CA240,116A CA1060795A (en) 1975-09-26 1975-11-20 Oil-free adjuvant composition containing muramyl dipeptide
JP51113813A JPS5244223A (en) 1975-09-26 1976-09-24 Oillfree composition including nnacetyllmuramyllllalanyllddisoglutamine
JP51113812A JPS5241211A (en) 1975-09-26 1976-09-24 Oillfree composition including nnacetyllmuramyllllalanyllddisoglutamine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/516,991 US4186194A (en) 1973-10-23 1974-10-22 Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents

Publications (2)

Publication Number Publication Date
FR2288527A2 true FR2288527A2 (en) 1976-05-21
FR2288527B2 FR2288527B2 (en) 1979-09-14

Family

ID=24057920

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7529624A Granted FR2288527A2 (en) 1974-10-22 1975-09-26 Oil-free adjuvant compsns causing no hypersensitisation - contg N-acetyl-muramyl-L-alanyl-D-isoglutamine pref in aq soln

Country Status (3)

Country Link
BE (2) BE834754R (en)
FR (1) FR2288527A2 (en)
ZA (2) ZA756661B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533827A1 (en) * 1982-09-30 1984-04-06 Anvar Composition possessing immunoregulatory properties, in particular of non-specific immunological adjuvants, based on muramyl peptide and an aluminium derivative
US4652449A (en) * 1982-07-05 1987-03-24 Centre National De La Recherche Scientifique (Cnrs) Encapsulating biological active substances into erythrocytes

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4397844A (en) * 1978-02-24 1983-08-09 Ciba-Geigy Corporation Antigen derivatives and processes for their preparation
FR2428050A1 (en) * 1978-06-05 1980-01-04 Anvar OLIGOMERS OF MURAMYL-PEPTIDE COMPOUNDS AND DRUGS CONTAINING THEM
US4368190A (en) 1980-04-17 1983-01-11 Merck & Co., Inc. Immunologically active dipeptidyl 4-O-,6-O-acyl-2-amino-2-deoxy-D-glucose derivatives and methods for their preparation
US4310514A (en) 1980-05-05 1982-01-12 Merck & Co., Inc. Immunologically active dipeptidyl 5-0,6-0-acyl-2-amino-2-deoxy-D-glucofuranose derivatives and methods of preparation
US4315913A (en) 1980-06-09 1982-02-16 Merck & Co. Inc. Immunologically active dipeptidyl 2-amino-1,2-dideoxy-D-glucose derivatives and methods of preparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2160326A1 (en) * 1971-11-19 1973-06-29 Anvar
DE2450355A1 (en) * 1973-10-23 1975-05-28 Anvar ADJUVANCES FORMED FROM N-ACYL-MURAMIC ACID DERIVATIVES AND VACCINES CONTAINING THEM

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2160326A1 (en) * 1971-11-19 1973-06-29 Anvar
DE2450355A1 (en) * 1973-10-23 1975-05-28 Anvar ADJUVANCES FORMED FROM N-ACYL-MURAMIC ACID DERIVATIVES AND VACCINES CONTAINING THEM

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652449A (en) * 1982-07-05 1987-03-24 Centre National De La Recherche Scientifique (Cnrs) Encapsulating biological active substances into erythrocytes
US4752586A (en) * 1982-07-05 1988-06-21 Centre National De La Recherche Scientifique Apparatus for encapsulating biological active substances into erythrocytes
FR2533827A1 (en) * 1982-09-30 1984-04-06 Anvar Composition possessing immunoregulatory properties, in particular of non-specific immunological adjuvants, based on muramyl peptide and an aluminium derivative

Also Published As

Publication number Publication date
BE834754R (en) 1976-02-16
FR2288527B2 (en) 1979-09-14
ZA756660B (en) 1976-11-24
BE834753R (en) 1976-02-16
ZA756661B (en) 1976-11-24

Similar Documents

Publication Publication Date Title
ATE258188T1 (en) RETRO, INVERSO, AND RETRO-INVERSO SYNTHETIC PEPTIDE ANALOGS
GR3019112T3 (en) Porcine reproductive respiratory syndrome vaccine and diagnostic.
IL91007A0 (en) Synthetic vaccine against aids virus
ES2109929T3 (en) PROCEDURE FOR PREPARING A YEAST GLUCAN
ES408766A1 (en) Process for preparing vaccine adjuvant
ES500567A0 (en) PROCEDURE FOR PREPARING VACCINATION COMPLEXES BY REACTION OF RIBONOSAL RNA AND SPECIFIC ANTIGENS.
FI102616B1 (en) Method for producing a vaccine against type 3 human parainfluenza virus and expression system useful in the method
FR2288527A2 (en) Oil-free adjuvant compsns causing no hypersensitisation - contg N-acetyl-muramyl-L-alanyl-D-isoglutamine pref in aq soln
DE3750139D1 (en) BACTERIAL ANTIGENS, ANTIBODIES, VACCINE AND THEIR PRODUCTION.
SE7602871L (en) VACCINE FOR ACTIVE IMMUNIZATION
Green Cytotoxic property of mouse cancer antiserum.
ATE149569T1 (en) METHOD FOR PRODUCING VACCINES OR TOXOIDS
ES379642A1 (en) Diethylaminoethyl dextran as an adjuvant for vaccines for active immunization
FI890603A0 (en) A method for producing an HIV particle immunogen and its antibody
BR9306187A (en) Bacterin-toxoid vaccine pasteurella haemolytica type a-1
KR890000106A (en) Protozoan Parasite Vaccine
RO76563A2 (en) PROCEDURE FOR STABILIZING AN ANTIHERPICAL VACCINE
BG21417A3 (en) METHOD FOR OBTAINING VIRAL STRAINS WHICH STIMULATE THE NATURAL DEFENSE MECHANISM OF THE HOST ORGANISM AND AT THE SAME TIME ARE FREE OF ANTIGENIC ACTION
Guthrie Foreign Bodies In The Air Passages
Smith PARENTERAL LIVER THERAPY
Morson Radium
Spahlinger The Spahlinger Vaccines
Anderson PARENTERAL LIVER THERAPY